Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database

ABC 1 Zhipeng Xu
D 2 Chuang Wang
E 1 Xuebao Xiang
F 1 Junming Li
G 1 Jiefu Huang

Corresponding Author: Jiefu Huang, e-mail: 601163132@qq.com
Source of support: This study was sponsored by Natural Science Foundation of Guangxi Province of China (2018GXNSFAA281356)

Background: Bladder cancer is a multifactorial disease with increasing incidence and mortality. Genetic alterations and altered expressions of mRNAs, long non-coding RNAs (lncRNAs), and miRNAs have been shown to play important roles in the tumorigenesis of bladder cancer. However, the functions of key RNAs and their regulatory network in bladder cancer are still to be elucidated.

Material/Methods: RNA profiles were downloaded from The Cancer Genome Atlas (TCGA) database. The differentially expressed mRNAs, lncRNAs, and miRNAs in bladder cancer were acquired through analyses of data from 414 bladder cancer tissues and 19 normal bladder tissues. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis was performed by using "DAVID6.8" and the R package "ClusterProfile". Protein–protein interaction and competing endogenous RNA (ceRNA) networks were constructed by using "STRING" database and Cytoscape 3.6.2. Based on the clinical data and Cox regression, a prognosis model was established, and survival analysis was performed.

Results: A total of 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were identified as significantly differentially expressed in bladder cancer of which 52 mRNAs, 58 lncRNAs, and 22 miRNAs were incorporated in the ceRNA network. CFL2 and TPM2 were found to be downregulated and showed significant correlation to each other in bladder cancer. HOXB5 and 6 lncRNAs (ADAMTS9-AS1, AC112721.1, LINC00460, AC110491.1, LINC00163, and HCG22) were strongly associated with high-grade, disease stages, and overall survival.

Conclusions: In this study, we have identified differentially expressed mRNAs, lncRNAs, and miRNAs in bladder cancer which were strongly associated with oncogenesis and prognosis. Further experimental studies are necessary to validate these results.

MeSH Keywords: Gene Expression • MicroRNAs • RNA, Long Noncoding • Urinary Bladder Neoplasms

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/915487
Background

Bladder cancer is one of the most malignant tumors with high incidence and mortality during the past decades [1]. In 2018, the incidence of bladder cancer was estimated to be approximately 81,000 new cases and the mortality to be 17,000 deaths in the United States (ranks sixth and eighth, respectively) [2]. Historically, approximately 95% of bladder cancer occurs in the urothelial cells, and around three-quarters of bladder cancer patients are non-muscle invasive bladder cancer while the rest are muscle invasive bladder cancer [3–5]. The grading of bladder cancer is crucial, and the World Health Organization (WHO) 2004/2016 grading system is preferred by most pathologists. Based on the cytologic and architectural abnormalities, atypia, low-grade, and high-grade determine the degree of malignancy and prognosis of bladder cancer [6,7]. Although new strategies for cancer diagnosis, detection, and neo-treatments have been developed for patients with bladder cancer in the past 30 years, the 5-year relative survival rate is still unsatisfactory [8]. Further research is thus essential to better understand the underlying pathogenetic mechanisms to improve the outcome of bladder cancer.

Recently, genetic characteristics and acquired genetic alterations have been found to play an important role in the bladder cancer. And these distinct mechanisms have been found to construct a multifocal network. For example, inactivating mutations in the tumor suppressor TP53 and activating mutations in FGFR3 are found in both papillary and non-papillary bladder cancer [9,10]. Moreover, mutations in genes encoding transcription factors and chromatin-modifying enzymes and mutations in TERT promoter are also strongly implicated in some cases [11–13].

With the development of high-throughput sequencing methods, thousands of pseudogenes have been characterized [14]. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been revealed to play a critical role in different kinds of cancer including bladder cancer, by modulating and modifying their ancestral gene. Our research group previously reported that lncRNA ROR was significantly increased in bladder cancer and positively associated with its potential targeting gene ZEB1, thereby contributing to the progression of bladder cancer as well as promoting epithelial-to-mesenchymal transition (EMT) [15]. Liu et al. demonstrated that lncRNA SRY4-IT1 sponges mir-101-3p and upregulates EZH2 leading to aggressive phenotypes in bladder cancer [16]. Therefore, characterization of an integrated whole differential gene expressions network with related endogenous RNA profiles is important, as it might play a key role in the pathogenesis of bladder cancer.

In this study, we identified the differentially expressed mRNA, lncRNA, and miRNA expression profiles in bladder cancer from the TCGA database. In addition, we performed functional analyses of the differentially expressed RNAs and investigated their clinical significance in relation to prognosis in bladder cancer.

Material and Methods

Patients and pathological data

Transcriptome profiling data of 414 bladder cancer tissues and 19 normal bladder tissues were acquired from The Cancer Genome Atlas (TCGA) in October 2018. The RNA-seq data were generated from the Illumina HiSeqRNASeq and Illumina HiSeqmiRNASeq platforms. Using the GDC Data Transfer Tool (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool), all the gene expression profiles and clinical data of bladder cancer were downloaded. Ethical consent was not required as all the data in this study were obtained from TCGA database.

Identification of differentially expressed RNA

The “DESeq” package in R software [17] was utilized to identify the differentially expressed RNAs in bladder cancer when compared to normal bladder tissues. The significance level of the adjusted P-value was set at P<0.01 and the thresholds was set as |log2FoldChange| ≥2. Moreover, the differentially expressed mRNAs, lncRNAs and miRNAs were annotated using ENSEMBL (https://www.ensembl.org/).

CeRNA network construction

According to the ceRNA theory, lncRNAs can act as endogenous RNA and thereby regulating target gene transcripts by competing with shared miRNAs [18]. Based on the differentially expressed mRNAs, lncRNAs and miRNAs in bladder cancer, the target mRNAs of the miRNAs were predicted by Targetscan (http://www.targetscan.org/), miRDB (http://www.mirdb.org/) and miRTarBase (http://miRTarbase.mbc.nctu.edu.tw) [19]. The miRanda database (http://www.microrna.org/) was used for the lncRNAs and miRNAs target predictions [20]. In addition, by combining the discriminatory expression profiles data, the interaction between lncRNAs and miRNAs was identified. The ceRNA network of mRNA-lncRNA-miRNA was visualized with Cytoscape v3.6.2.

Functional enrichment analysis

Gene Ontology (GO) enrichment analysis was performed by (DAVID 6.8) database (http://david.abcc.ncifcrf.gov/) to group the differentially expressed RNAs into 3 categories including molecular function, biological process, and cellular component. The setting in the GO analysis was a false discovery rate (FDR) <0.01. The “ClusterProfiler” package in R software was utilized.
to analyze the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The barplots for GO and KEGG were generated by the “Goplot” package.

**Prognosis risk scoring in differentially expressed RNAs**

Univariate Cox regression analysis was conducted where \( P < 0.0005 \) was considered statistically significant. The significant mRNAs in univariate Cox regression were subsequently analyzed in a multivariate Cox regression proportional hazards model. Furthermore, based on the median risk score, bladder cancer patients were divided into “high-risk” and “low-risk” groups. The risk scoring system was constructed by the formula as follows for predicting overall survival (OS): 

\[
\text{risk score} = \sum b_g \times \text{expr}_g
\]

Kaplan-Meier survival analysis and receiver operating characteristic (ROC) analysis were then performed to assess the risk scoring system with high and low scores. The survival and ROC analyses were accomplished by using the R package “survival” and “survivalROC”.

**Protein–protein interaction (PPI) and correlation network construction**

The differentially expressed mRNAs in the ceRNA network were analyzed through the protein–protein interaction (PPI) network. The PPI network was constructed with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). The minimum interaction value was set at low confidence (0.150). Based on the top 10 combined prediction score, we selected these gene expression profiles to perform correlation analyses for further validation.

**Genes associated with grading and staging in ceRNA network and survival analysis**

Differentially expressed mRNA, lncRNA, and miRNA in the ceRNA network were analyzed in relation to low-grade and high-grade bladder cancer. These aberrantly expressed RNAs were also evaluated in relation to tumor stage. The significance level of adjusted \( P \)-value was <0.01 and the thresholds was set as \(|\log2\text{FoldChange}| > 2\). Kaplan-Meier plots and log-rank test was performed to evaluate the genes in relation to overall survival, where \( P < 0.05 \) was considered as statistically significant.

**Results**

**Characteristics of clinical features in TCGA database**

Clinical information of bladder cancer patients from the TCGA database was available in 412 of 433 cases. The clinical characteristics including age, gender, tumor grade, tumor stage, and lymph node metastasis of the bladder cancer patients are presented in Table 1. Interestingly, except for gender, all other clinical features were significantly associated with survival. Patients with high-grade bladder cancer were associated with worse outcomes compared to patients with low-grade bladder cancer. The median age of the cohort was 69 years (range: 34–90 years).

### Table 1. The clinicopathological characteristics of bladder cancer patients.

| Characteristics | Subtype      | Patients n (%) | Dead | \( \chi^2 \) | P-value |
|-----------------|--------------|----------------|------|-------------|---------|
| Age             | >65          | 250 (60.7)     | 115  | 14.722      | <0.01   |
|                 | ≤65          | 162 (39.3)     | 44   |             |         |
| Gender          | Male         | 304 (73.8%)    | 115  | 0.285       | 0.593   |
|                 | Female       | 108 (26.2%)    | 44   |             |         |
| Tumor grade     | High grade   | 388 (94.2%)    | 159  | 16.016      | <0.01   |
|                 | Low grade    | 24 (5.8%)      | 0    |             |         |
| Tumor Stage     | Stage I and II| 133 (32.3%)   | 27   | 27.728      | <0.01   |
|                 | Stage III and IV | 279 (67.7%) | 132  |             |         |
| Lymph node      | Negative     | 239 (58.0%)    | 63   | 37.810      | <0.01   |
|                 | Positive     | 131 (31.8%)    | 77   |             |         |
|                 | Unknow       | 42 (10.2%)     | 19   |             |         |

N=412.
Differentially expressed RNAs and ceRNA network in bladder cancer

A total of 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were found to be differentially expressed in bladder cancer, of which 1030 mRNAs (56.7%), 415 lncRNAs (63.0%) and 139 miRNAs (86.9%) were upregulated while others were downregulated. The differentially expressed RNAs are visualized in the volcano plot (Figure 1). We further validated the relationships and functions of these differentially expressed RNAs according to the ceRNA hypothesis. The miRNA-mRNA and lncRNA-miRNA interactions were first predicted to find 52 mRNAs targeted by at least one differentially expressed miRNA.

Table 2. Differentially expressed miRNAs targeting mRNAs in the ceRNA network.

| miRNA  | mRNA                               |
|--------|------------------------------------|
| miR-141| EPHA7; ZEB1; ELAVL2; HOXB5          |
| miR-145| MEST                               |
| miR-182| FGF9; THBS1; TCEAL7; ULBP2; PRKAA2  |
| miR-183| AKAP12; ZEB1; CCNB1                 |
| miR-195| BTG2; TPM2; RUNX1T1; FGF2; TGFB3; CXB2; PRICKLE2; MYB; WNT7A; MKX; ALOX12; ITPR1; CCNE1; RAB23; TMEM100; E2F7 |
| miR-200a| HOXB5; EPHA7; ZEB1; ELAVL2; CCNE2   |
| miR-205| ZEB1; SHISA6; LRRK2                |
| miR-210| SERTM1; AIFM3; NR4A2               |
| miR-217| NR4A2; MAP1B                       |
| miR-31 | SELE; HOXC13                       |
| miR-372| DUSP2; CADM2; TMEM100; FBXL7; ELAVL2 |
| miR-373| CADM2; TMEM100; FBXL7; ELAVL2; CFL2; DUSP2 |
| miR-383| DIO1                               |
| miR-429| JUN; ZEB1; ZFPM2                    |
| miR-503| GREM2                              |
| miR-519d| NACC2; HMGB3; CYBRD1; SALL3; CFL2; FAM129A; DUSP2; POLQ; ELAVL2 |
| miR-96 | SLC25A25; ZEB1                      |

Figure 1. Differentially expressed RNAs in bladder cancer are visualized by volcano plots. The red dots show upregulated genes while the green dots show downregulated genes. (A) Differentially expressed mRNAs in bladder cancer. (B) Differentially expressed lncRNAs in bladder cancer. (C) Differentially expressed miRNAs in bladder cancer.
by 17 key miRNAs involved in ceRNAs network (Table 2) and 58 lncRNAs were predicted to be interacted with 22 miRNAs (Table 3). As a result, 52 mRNAs, 58 lncRNAs, and 22 miRNAs of the differentially expressed RNAs were incorporated in the established ceRNA network (Tables 4–6). In this ceRNA network, 16 mRNAs, 35 lncRNAs, and 17 miRNAs were downregulated; while 36 mRNAs, 23 lncRNAs, and 5 miRNAs were found to be upregulated (Figure 2).

**GO and KEGG functional analysis**

To further elucidate the functions and biological processes of the differentially expressed mRNAs, we conducted the GO and KEGG enrichment analysis. The barplot of the GO analysis showed significant enrichment in 26 molecular functions, biological processes, and cellular components (P-value <0.001) (Figure 3A). The results revealed that 313 genes were aggregated in extracellular region with the lowest P-value at 1.15E-36. KEGG pathway analysis showed that 20 pathways were associated with tumorigenesis of bladder cancer. As shown in Figure 3B, the neuroactive ligand-receptor interaction reflects

| LncRNA       | miRNA                     |
|--------------|---------------------------|
| IGF2-AS      | miR-519d; miR-503         |
| LINCO00525   | miR-301b; miR-96; miR-141; miR-200a; miR-182; miR-31; miR-383 |
| PART1        | miR-301b; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-429; miR-205; miR-31 |
| AC009065.1   | miR-372; miR-373         |
| C20orf166-AS1| miR-301b; miR-372; miR-373; miR-519d; miR-183; miR-429; miR-205; miR-489 |
| miR-145      | miR-372; miR-205; miR-383 |
| C20orf197    | miR-372; miR-373; miR-143; miR-519d; miR-383 |
| AP002478.1   | miR-503; miR-372; miR-373; miR-195; miR-519d; miR-182; miR-192; miR-215; miR-205; miR-489 |
| LINCO00518   | miR-141; miR-200a; miR-143; miR-145 |
| LINCO00482   | miR-143                  |
| MIR22HG      | miR-383; miR-489         |
| C9orf163     | miR-143; miR-195; miR-205; miR-489 |
| LINCO00336   | miR-96; miR-143; miR-145; miR-217 |
| AC008676.1   | miR-301b; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-519d; miR-31 |
| PART1        | miR-372; miR-373; miR-143; miR-183; miR-205; miR-31 |
| AC104472.1   | miR-143; miR-183; miR-429; miR-31; miR-489 |
| AC0487      | miR-141; miR-200a; miR-183 |
| LINCO00473   | miR-145; miR-195; miR-210 |
| LINCO00337   | miR-372; miR-373; miR-145; miR-519d; miR-182; miR-217; miR-383 |
| AC127496.3   | miR-301b; miR-372; miR-373; miR-145; miR-183; miR-192; miR-215; miR-429 |
| LINCO00161   | miR-145; miR-205         |
| HCG22        | miR-96; miR-145; miR-195; miR-182; miR-31; miR-383; miR-489 |
| SACS-AS1     | miR-503; miR-372; miR-143; miR-205 |
| MIR137HG     | miR-182; miR-192; miR-215 |
### Differentially expressed miRNAs targeting lncRNAs in ceRNA network.

| LncRNA          | miRNA                  |
|-----------------|------------------------|
| RASA3-IT1       | miR-205; miR-383       |
| NALCN-AS1       | miR-372; miR-373; miR-195; miR-182; miR-205; miR-31; miR-383 |
| ERVH48-1        | miR-301b; miR-96; miR-141; miR-200a; miR-145; miR-182 |
| LINC00472       | miR-503; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-383; miR-489 |
| AC110491.1      | miR-141; miR-200a; miR-143; miR-182; miR-192; miR-215; miR-429; miR-205; miR-489 |
| TLR8-A51        | miR-182; miR-31       |
| LINC00460       | miR-503; miR-143; miR-429; miR-489 |
| JAZF1-AS1       | miR-372; miR-373; miR-143; miR-519d; miR-205 |
| MAGI2-AS3       | miR-503; miR-372; miR-373; miR-141; miR-200a; miR-143; miR-145; miR-195; miR-429; miR-210; miR-217; miR-31; miR-489 |
| LINC00163       | miR-143; miR-183; miR-210 |
| LINC00330       | miR-503; miR-301b; miR-372; miR-373; miR-145; miR-195; miR-519d; miR-192; miR-215; miR-205; miR-383 |
| LINC00402       | miR-141; miR-200a; miR-143; miR-519d; miR-182; miR-429; miR-217; miR-383 |
| TM4SF19-A51     | miR-141; miR-200a; miR-205 |
| MVO16-AS1       | miR-480 |
| DLEU7-A51       | miR-96; miR-195; miR-182; miR-192; miR-215 |
| AC009121.1      | miR-141; miR-200a |
| AC112721.1      | miR-503; miR-195       |
| AP004609.1      | miR-383               |
| ADAMTS9-AS1     | miR-301b; miR-301b; miR-143; miR-182; miR-183; miR-31 |
| ADAMTS9-AS2     | miR-301b; miR-372; miR-373; miR-96; miR-141; miR-200a; miR-143; miR-145; miR-182; miR-183; miR-205; miR-31 |
| AC078778.1      | miR-301b               |
| AC012640.1      | miR-182; miR-205; miR-210; miR-383 |
| AC073352.1      | miR-96; miR-182       |
| AC011453.1      | miR-143; miR-205       |
| AP000553.1      | miR-192; miR-215; miR-217 |
| AC128709.1      | miR-503; miR-195; miR-183 |
| LINC00534       | miR-372; miR-373; miR-96; miR-192; miR-215; miR-205; miR-217; miR-489 |
| NAV2-AS2        | miR-96; miR-182; miR-31 |
| ARAP1-AS1       | miR-145               |
| FRMD6-AS2       | miR-143; miR-182       |
| LINC00520       | miR-503; miR-372; miR-373; miR-145; miR-195; miR-519d; miR-205; miR-217; miR-31 |
| DEmRNAs | Regulation | Log fold change | FDR      |
|---------|------------|-----------------|----------|
| CFL2    | Down-regulation | -3.1877341     | 6.81E-64 |
| SLC25A25| Down-regulation  | -2.65657164     | 1.81E-63 |
| FAM129A | Down-regulation  | -3.684416254    | 2.52E-60 |
| NACC2   | Down-regulation  | -2.417159742    | 5.97E-48 |
| RAB23   | Down-regulation  | -2.902696027    | 1.86E-43 |
| ITPR1   | Down-regulation  | -2.677318488    | 4.37E-38 |
| ZEB1    | Down-regulation  | -2.830314677    | 2.64E-37 |
| MAP1B   | Down-regulation  | -3.224125414    | 1.18E-34 |
| NR4A2   | Down-regulation  | -2.806554541    | 9.69E-33 |
| TPM2    | Down-regulation  | -3.056564907    | 1.34E-30 |
| FBXL7   | Down-regulation  | -2.52708691     | 5.43E-28 |
| THBS1   | Down-regulation  | -2.686969518    | 7.25E-25 |
| PRICKLE2| Down-regulation  | -2.241943525    | 9.47E-25 |
| JUN     | Down-regulation  | -2.081270648    | 1.94E-23 |
| ZFPM2   | Down-regulation  | -2.664653755    | 3.11E-23 |
| AKAP12  | Down-regulation  | -2.592811618    | 8.39E-22 |
| TMEM100 | Down-regulation  | -3.095618096    | 4.25E-20 |
| TCEAL7  | Down-regulation  | -2.49946        | 5.49E-20 |
| EPHA7   | Down-regulation  | -3.166          | 9.53E-20 |
| FGF2    | Down-regulation  | -2.69593        | 9.99E-19 |
| RLINX1T1| Down-regulation  | -2.57174        | 1.52E-18 |
| LRRK2   | Down-regulation  | -2.36765        | 2.55E-18 |
| BTG2    | Down-regulation  | -2.13366        | 6.79E-18 |
| CYBRD1  | Down-regulation  | -2.17256        | 8.81E-18 |
| MKX     | Down-regulation  | -3.12218        | 1.49E-17 |
| HMGB3   | Up-regulation    | 2.057653        | 1.33E-16 |
| PRKAA2  | Down-regulation  | -2.63399        | 1.31E-15 |
| TGFBR3  | Down-regulation  | -2.442571       | 1.38E-15 |
| DUSP2   | Down-regulation  | -2.49447        | 8.28E-15 |
| GREM2   | Down-regulation  | -3.03523        | 2.37E-14 |
| CCNB1   | Up-regulation    | 2.066358        | 1.53E-12 |
| SERTM1  | Down-regulation  | 3.83855         | 2.49E-12 |
| SHISA6  | Down-regulation  | -2.77251        | 3.62E-11 |
| CCNE1   | Up-regulation    | 2.305447        | 2.37E-10 |
Table 4 continued. Differentially expressed mRNAs in ceRNA network.

| DelmRNAs | Regulation | Log fold change | FDR   |
|----------|------------|-----------------|-------|
| FGF9     | Up-regulation | 2.519249       | 2.45E-10 |
| SELE     | Down-regulation | -2.78825      | 7.82E-10 |
| E2F7     | Down-regulation | -2.47734      | 1.80E-09 |
| CCNE2    | Up-regulation | 2.254535       | 6.75E-09 |
| ALOX12   | Up-regulation | 2.116593       | 6.91E-09 |
| ULBP2    | Down-regulation | -2.00117      | 1.01E-08 |
| MEST     | Up-regulation | 2.464683       | 7.47E-08 |
| CBX2     | Up-regulation | 2.595458       | 1.57E-06 |
| CADM2    | Up-regulation | 2.183717       | 3.23E-06 |
| HOXC13   | Down-regulation | -2.25318      | 2.10E-05 |
| MYB      | Up-regulation | 2.796581       | 4.20E-05 |
| SALL3    | Up-regulation | 2.034968       | 4.76E-05 |
| AIFM3    | Down-regulation | -2.55675      | 0.000173 |
| HOXB5    | Up-regulation | 2.147751       | 0.000211 |
| WNT7A    | Up-regulation | 2.024795       | 0.000334 |
| ELAVL2   | Up-regulation | 6.532413       | 0.000532 |
| DIO1     | Up-regulation | 3.143323       | 0.000581 |

Table 5. Differentially expressed lncRNAs in ceRNA network.

| DelncRNAs | Regulation | Log fold change | FDR  |
|-----------|------------|-----------------|------|
| HCG22     | Down-regulation | -7.393236357   | 8.70E-86 |
| ADAMTS9-A51 | Down-regulation | -5.173460141   | 1.28E-59 |
| ADAMTS9-A52 | Down-regulation | -4.152710881   | 3.17E-50 |
| LINC00330 | Down-regulation | -5.357713971   | 8.39E-35 |
| C20orf166-A51 | Down-regulation | -4.418702998   | 7.39E-34 |
| MIR22HG   | Down-regulation | -2.186866609   | 2.83E-29 |
| JAZF1-A51 | Down-regulation | -3.248756128   | 2.20E-26 |
| AC008676.1 | Down-regulation | -2.677691052   | 1.61E-22 |
| RASA3-IT1 | Down-regulation | -4.319901412   | 8.29E-20 |
| MAGI2-A53 | Down-regulation | -2.271922028   | 1.15E-18 |
| FRMD6-A52 | Down-regulation | -3.536986684   | 6.70E-18 |
| PART1     | Down-regulation | -2.883633316   | 5.25E-16 |
| AC110491.1 | Down-regulation | -3.809886233   | 5.66E-16 |
| AC078778.1 | Up-regulation  | 2.171874229    | 2.62E-14 |
Table 5 continued. Differentially expressed IncRNAs in ceRNA network.

| DELncRNAs | Regulation | Log fold change | FDR     |
|-----------|------------|----------------|---------|
| SACS-AS1  | Down-regulation | −3.387765888 | 1.98E-13 |
| AP004609.1| Down-regulation | −2.579281355 | 2.67E-11 |
| C9orf163  | Up-regulation  | 2.339600002  | 6.13E-11 |
| LINC00472 | Down-regulation | −2.086567223 | 5.03E-10 |
| AC127496.3| Down-regulation | −2.91629805  | 7.40E-10 |
| GRIK1-AS1 | Down-regulation | −2.185078089 | 8.15E-10 |
| AC003352.1| Up-regulation  | 2.540191221  | 3.51E-09 |
| NALCN-AS1 | Down-regulation | −2.49519035  | 8.70E-09 |
| AP000553.1| Up-regulation  | 2.16908948   | 1.44E-08 |
| LINC00163 | Down-regulation | −2.829231994 | 1.25E-07 |
| AC009121.1| Up-regulation  | 2.162583137  | 1.08E-06 |
| LINC00460 | Up-regulation  | 7.163558998   | 1.22E-06 |
| DLEU7-AS1 | Up-regulation  | 2.139118702  | 3.54E-06 |
| LINC00337 | Up-regulation  | 2.01874432   | 4.36E-06 |
| AP000525.1| Up-regulation  | 2.750867634  | 1.26E-05 |
| ALS13123.1| Up-regulation  | 3.339752428  | 1.64E-05 |
| LINC00161 | Down-regulation | −2.004179345 | 2.13E-05 |
| LINC00402 | Down-regulation | −2.228396776 | 2.28E-05 |
| C2orf48   | Up-regulation  | 2.234385723  | 2.41E-05 |
| AC112721.1| Up-regulation  | 5.679017823  | 2.64E-05 |
| ERVH48-1  | Up-regulation  | 6.171777638  | 3.07E-05 |
| TM4SF19-AS1| Up-regulation | 2.241213677  | 5.71E-05 |
| LINC00529 | Up-regulation  | 2.388170307  | 7.58E-05 |
| AP002478.1| Up-regulation  | 2.499724256  | 7.88E-05 |
| AC011453.1| Up-regulation  | 4.106228298  | 0.000145979 |
| C2orf197  | Up-regulation  | 3.22909721   | 0.000173251 |
| LINC00487 | Up-regulation  | 2.684913886  | 0.0001926 |
| AC012640.1| Up-regulation  | 3.267430057  | 0.000198949 |
| AC009065.1| Up-regulation  | 2.02957356   | 0.000245796 |
| LINC00518 | Up-regulation  | 4.436236799  | 0.000596273 |
| AC104472.1| Up-regulation  | 2.743663788  | 0.001205612 |
| MYO16-AS1 | Up-regulation  | 4.783639374  | 0.001480169 |
| HNF1A-AS1 | Up-regulation  | 3.838602554  | 0.001551329 |
| LINC00534 | Up-regulation  | 2.943676684  | 0.002062953 |

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
### Table 5. Differentially expressed lncRNAs in ceRNA network.

| DElncRNAs  | Regulation  | Log fold change | FDR       |
|------------|-------------|-----------------|-----------|
| LINC00520  | Up-regulation | 3.918845469 | 0.002229151 |
| LINC00482  | Up-regulation | 2.211556791 | 0.003470315 |
| LINC00473  | Down-regulation | -2.010751587 | 0.003738568 |
| LINC00336  | Up-regulation | 2.001908125 | 0.003803458 |
| TLR8-AS1   | Up-regulation | 4.005367912 | 0.003995111 |
| MIR137HG   | Up-regulation | 5.171531584 | 0.004865838 |
| NAV2-AS2   | Up-regulation | 3.18541719  | 0.006297113 |
| ARAP1-AS1  | Up-regulation | 3.112442765 | 0.008604833 |
| IGFI-AS    | Up-regulation | 2.39553974  | 0.008980377 |

### Table 6. Differentially expressed lncRNAs in ceRNA network.

| DEMiRNAs | Regulation  | Log fold change | FDR       |
|----------|-------------|-----------------|-----------|
| hsa-mir-143 | Down-regulation | -3.52679542 | 1.28E-41  |
| hsa-mir-195 | Down-regulation | 2.140476303 | 1.25E-32  |
| hsa-mir-96  | Up-regulation | 3.767149943 | 8.97E-18  |
| hsa-mir-210 | Up-regulation | 4.973834298 | 1.33E-17  |
| hsa-mir-3199-2 | Down-regulation | -2.187131639 | 1.55E-15  |
| hsa-mir-145 | Down-regulation | -2.13372137 | 3.72E-14  |
| hsa-mir-183 | Up-regulation | 3.03501324 | 8.81E-14  |
| hsa-mir-301b | Up-regulation | 3.971849748 | 1.19E-12  |
| hsa-mir-141 | Up-regulation | 2.631026555 | 3.23E-11  |
| hsa-mir-503 | Up-regulation | 2.473934298 | 3.22E-10  |
| hsa-mir-182 | Up-regulation | 2.44870325 | 3.51E-10  |
| hsa-mir-429 | Up-regulation | 2.758180811 | 6.74E-09  |
| hsa-mir-383 | Down-regulation | -2.801221137 | 3.16E-08  |
| hsa-mir-200a | Up-regulation | 2.219506844 | 2.94E-07  |
| hsa-mir-192 | Up-regulation | 2.40248191 | 6.49E-07  |
| hsa-mir-205 | Up-regulation | 2.239011007 | 8.69E-06  |
| hsa-mir-215 | Up-regulation | 4.242318245 | 2.68E-05  |
| hsa-mir-31  | Up-regulation | 2.786222534 | 3.19E-05  |
| hsa-mir-3136 | Up-regulation | 2.306880974 | 4.63E-05  |
| hsa-mir-519d | Up-regulation | 7.14700051 | 0.00104682 |
| hsa-mir-372 | Up-regulation | 5.986379084 | 0.000186072 |
| hsa-mir-489 | Up-regulation | 2.962732727 | 0.000303842 |
the most significant cancer associated pathway which contained 61 genes, followed by alcoholism with 59 genes enriched.

**Prognostic risk score based on differentially expressed mRNAs**

Of the 1820 differentially expressed mRNAs, we found 36 mRNAs to be significantly associated with survival using univariate Cox regression (Table 7). Subsequently, multivariate Cox regression was applied, and 12 mRNA expression profiles were identified as coupled to overall survival and included in the overall survival prediction model (Figure 4A, 4B). On the basis of the overall survival prediction model, a prognostic risk model was constructed where the high-risk group was significantly associated with lower overall survival ($P < 0.05$) (Figure 4B). The discriminative evaluation of the risk scoring system was performed with ROC-curve analysis where we found an AUC=0.735 (Figure 4C).

**PPI network**

In order to identify the gene interactions of the differentially expressed mRNAs in the ceRNA network, a PPI network was constructed with these 52 aberrantly expressed genes. In total, 44 nodes and 144 edges were constituted in the single PPI network by STRING (Figure 5A). JUN was identified to have the largest number of edges interacting with 28 other genes. Nodes which connect with more than 4 genes are listed in the barplot (Figure 5B). Based on the predicted combined score for each pair of nodes from STRING, the top 10 correlating mRNAs are presented in Table 8. We then proceeded by validating the 10 correlations with Pearson's correlation and as shown in Figure 6, we found a strong correlation between CFL2 and TPM2 ($r=0.911$) and between CCNE2 and E2F7 ($r=0.734$), respectively (Figure 6). The results indicated that there was an interaction between CFL2 and TPM2 and between CCNE2 and E2F7 respectively, in bladder cancer.

![Figure 2. The ceRNA network of differentially expressed RNA profiles in bladder cancer, the upregulated genes are presented using red color while downregulated genes are shown using green color. Circles represent mRNAs, quadrangles represent lncRNAs and rhombus represent miRNAs.](image)
Figure 3. GO and KEGG analysis of differentially expressed mRNAs in bladder cancer. (A) Twenty-six significant molecular functions, biological processes, and cellular components of differentially expressed mRNAs. (B) Twenty enrichment of KEGG pathways for differentially expressed mRNAs. GO – Gene Ontology; KEGG – Kyoto Encyclopedia of Genes and Genomes.

Table 7. Significant genes demonstrated in univariate Cox regression model (P<0.005).

| Gene   | HR       | z-score   | P-value   |
|--------|----------|-----------|-----------|
| EMP1   | 1.328726228 | 5.254914697 | 1.48E-07  |
| MXRA7  | 1.432626177 | 4.705964739 | 2.53E-06  |
| SERPINB12 | 1.162296991 | 4.580143916 | 4.66E-06  |
| MAP1B  | 1.229296929 | 4.37622915  | 1.21E-05  |
| LAMA2  | 1.267134732 | 4.327829003 | 1.51E-05  |
| KANK4  | 1.113571638 | 4.182201609 | 2.89E-05  |
| ABC9   | 1.231009469 | 4.178191876 | 2.94E-05  |
| PEX5L  | 1.162984335 | 4.138450231 | 3.50E-05  |
| PTGER3 | 1.144526818 | 4.026382546 | 5.66E-06  |
| PTPRR  | 0.898457289 | -3.961993355 | 3.13E-05  |
| POU5F1 | 0.857411853 | -3.875204799 | 0.000106535 |
| PCSK9  | 1.102595243 | 3.853707011 | 0.000116343 |
| TCHH   | 1.135841746 | 3.841592708 | 0.000122239 |
| SAPCD1 | 0.791832106 | -3.813548024 | 0.000136986 |
| GABRG1 | 1.312711858 | 3.80120357 | 0.000143999 |
| CNTN1  | 1.105824108 | 3.792658288 | 0.000149043 |
| ADCYAP1R1 | 1.159131884 | 3.76366481 | 0.000167441 |
| CCDC80 | 1.145347666 | 3.757185989 | 0.000171832 |
| MAP1A  | 1.233776119 | 3.745557523 | 0.000183613 |
| DTNA   | 1.179886946 | 3.740557523 | 0.000183613 |
Table 7 continued. Significant genes demonstrated in univariate Cox regression model (P<0.005).

| Gene     | HR     | z-score | P-value |
|----------|--------|---------|---------|
| RBMS3    | 1.20   | 3.69    | 0.0002  |
| XAGE2    | 1.11   | 3.69    | 0.0002  |
| PLEKHM4B | 1.06   | 3.69    | 0.0002  |
| NTNG1    | 1.12   | 3.69    | 0.0002  |
| FBN2     | 1.03   | 3.69    | 0.0002  |
| FLNC     | 1.11   | 3.69    | 0.0002  |
| GHR      | 1.18   | 3.69    | 0.0002  |
| PRK1     | 1.14   | 3.69    | 0.0002  |
| TNFAIP8L3| 1.17   | 3.69    | 0.0002  |
| ADRA1D   | 1.17   | 3.69    | 0.0002  |
| AIFM3    | 0.58   | -3.69   | 0.0002  |
| ABCA4    | 1.10   | 3.69    | 0.0002  |
| SRPX     | 1.14   | 3.69    | 0.0002  |
| CACNA2D1 | 1.16   | 3.69    | 0.0002  |

Figure 4. Survival analysis and Cox regression. (A) A heatmap of 12 significant mRNA expression profile for prediction of overall survival by multivariate cox regression. (B) Twelve mRNA expression profiles for prediction of overall survival in bladder cancer by multivariate Cox regression. (C) Kaplan-Meier plot shows statistical significance between high-risk and low-risk groups by risk scoring model (P<0.05). (D) The ROC curve for the risk scoring model (AUC=0.735). ROC – receiver operating characteristic, AUC – area under the curve.
Clinicopathological features related gene expression in ceRNA network

We further analyzed the relationship between the differentially expressed RNAs in the ceRNA network in relation to clinicopathological features. As a result, we found 5 mRNAs, 21 lncRNAs, and 6 miRNAs to be differentially expressed among high-grade and low-grade bladder cancer (Figure 7, Table 9). In addition, of these RNAs, 2 out of 5 mRNAs (HOXB5, MKX) and 10 out of 21 lncRNAs (AC112721.1, ADAMTS9-AS1, AP004609.1, LINC00460, AC110491.1, C20orf166-AS1, LINC00163, ARAP1-AS1, HCG22, LINC00473) were found to be significantly differentially expressed across stage I, stage II, stage III, and stage IV (Figure 8). The rest of the RNAs were not associated with tumor stage in bladder cancer (P>0.05) (Supplementary Figure 1). In relation to prognosis, 1 mRNA (HOXB5) and 6 lncRNAs (ADAMTS9-AS1, AC112721.1, LINC00460, AC110491.1, LINC00163, HCG22) were observed to be associated with overall survival (Figure 9).
Figure 6. The correlation plots of the top 10 predicted combined model.

Figure 7. A heatmap of differentially expressed genes in the ceRNA network associated with high-grade bladder cancer. (A) Differentially expressed mRNAs in ceRNA network associated with high-grade bladder cancer. (B) Differentially expressed IncRNAs in ceRNA network associated with high-grade bladder cancer. (C) Differentially expressed miRNAs in ceRNA network associated with high-grade bladder cancer.
Molecular and genetic alterations in bladder cancer have been extensively studied in the past decades. Clinicopathological features, including tumor grade and stage, have been shown to be linked to biological and genetic mechanisms [22–24]. However, clinical challenges still exist for bladder cancer, making it crucial to focus on new prediction methods based on the molecular targets.

In this study, we have conducted an integrated characterization of RNA expression profiles and performed ceRNA network analysis in bladder cancer based on data from the TCGA database. As a result, 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were identified as differentially expressed. The table below summarizes the top differentially expressed RNA profiles correlating to high-grade bladder cancer from the ceRNA network.

| RNAs                  | Log fold change | FDR     |
|-----------------------|-----------------|---------|
| HOXB5(mRNA)           | -2.944596082    | 2.39E-18|
| MKX(mRNA)             | 3.512064708     | 3.98E-08|
| SALL3(mRNA)           | -3.09599773     | 6.86E-07|
| ELAVL2(mRNA)          | 3.104383407     | 0.000197897|
| SELE(mRNA)            | 2.725611899     | 0.000649315|
| LINC00336(lncRNA)     | -2.274109048    | 1.50E-09|
| ARAP1-AS1(lncRNA)     | -2.922663469    | 3.31E-09|
| LINC00460(lncRNA)     | 6.246084381     | 1.13E-06|
| AC112721.1(lncRNA)    | 6.126188656     | 1.90E-06|
| ADAAMTS9-AS1(lncRNA)  | 4.959254878     | 8.37E-06|
| C2orf48(lncRNA)       | 2.14039587      | 2.37E-05|
| MIR137HG(lncRNA)      | 6.327534674     | 5.76E-05|
| LINC00473(lncRNA)     | 5.415263905     | 6.33E-05|
| LINC00163(lncRNA)     | 4.423919282     | 6.33E-05|
| AC110491.1(lncRNA)    | 4.746368747     | 0.000165643|
| LINC00402(lncRNA)     | 3.533793424     | 0.000229383|
| MYO16-AS1(lncRNA)     | 5.102890535     | 0.000231527|
| LINC00520(lncRNA)     | 4.493602761     | 0.000289874|
| HCG22(lncRNA)         | 6.362121452     | 0.000499845|
| TLR8-AS1(lncRNA)      | 4.019357381     | 0.000964633|
| C20orf166-AS1(lncRNA) | 3.194349357     | 0.001177387|
| LINC00518(lncRNA)     | 2.965146588     | 0.004120812|
| AP004609.1(lncRNA)    | 2.067991973     | 0.004431864|
| SACS-AS1(lncRNA)      | 2.266344736     | 0.026097183|
| LINC00330(lncRNA)     | 2.19115354      | 0.034777432|
| AC127496.3(lncRNA)    | 2.19115354      | 0.034777432|
| hasa-mir-143(miRNA)   | 3.330527062     | 0.00099772|
| hasa-mir-215(miRNA)   | 2.871943848     | 0.00212078|
| hasa-mir-217(miRNA)   | 3.321184311     | 0.0023354727|
| hasa-mir-372(miRNA)   | 4.593394591     | 0.00371048|
| hasa-mir-373(miRNA)   | 4.640595006     | 0.0118349|

Table 9. Differentially expressed RNA profiles correlating to high-grade bladder cancer from the ceRNA network.

Discussion

Molecular and genetic alterations in bladder cancer have been extensively studied in the past decades. Clinicopathological features, including tumor grade and stage, have been shown to be linked to biological and genetic mechanisms [22–24]. However, clinical challenges still exist for bladder cancer making it crucial to focus on new prediction methods based on the molecular targets.

In this study, we have conducted an integrated characterization of RNA expression profiles and performed ceRNA network analysis in bladder cancer based on data from the TCGA database. As a result, 1819 mRNAs, 659 lncRNAs, and 160 miRNAs were identified as differentially expressed, highlighting the potential of these molecules as biomarkers for better diagnosis and management of bladder cancer.
were found to be differentially expressed in bladder cancer, of which 52 mRNAs, 58 lncRNAs, and 22 miRNAs were predicted to be involved in the ceRNA network. Furthermore, high-grade bladder cancer related RNA profiles were identified consisting of 5 mRNAs, 21 lncRNAs, and 6 miRNAs, of which 2 mRNAs and 10 lncRNAs were found to be associated with stage as well.

Based on the current findings of 1819 differentially expressed RNAs, our functional enrichment analysis indicated that these genes were mainly enriched in "extracellular region". Similarly, GO analysis of prostate cancer conducted by Jiang et al. showed that most of the differentially expressed mRNAs in the urinary system were aggregated in the

**Figure 8.** Histograms of differentially expressed genes in the ceRNA network related to high-grade bladder cancer and disease stages. (A) Two significant mRNA expressions across different tumor stages. (B) Ten significant IncRNAs expressions across different tumor stages.

**Figure 9.** The Kaplan-Meier plots of differentially expressed RNAs in the ceRNA network which are also related to high-grade, stages, and overall survival.
extracellular region [25]. In addition, we predicted that 61 genes were enriched in the neuroactive ligand-receptor interaction, including PDGFR-α. Activation of PDGFR-α have previously been implicated in bladder tumor progression by a ras- and Src-independent activation of MEK/ERK pathway [26]. Interestingly, systematic lupus erythematosus and alcoholism were identified as important components in the occurrence and development of bladder cancer as previously reported [27,28].

Based on the results from the Cox regression, we successfully established an overall survival prediction model based on 12 mRNA expression profiles. The discriminative value of these genes combined was an AUC at 0.735. Of these 12 genes, the tumor necrosis factor-α induced protein 8 TNFAIP8, has been shown to be strongly associated to cancer progression [29]. However, except for TNFAIP8 in the prediction model, the other 11 genes have not yet been elucidated in bladder cancer. Hence, the prognostic value of the prediction model should be further demonstrated in future studies.

Through our analysis of the PPI network, we identified that JUN, known as c-jun, plays a vital role in the differentially expressed mRNAs in our ceRNA network. In the analysis, we found that JUN has the most edges and interacts with 28 other genes. JUN is an AP-1 transcription factor subunit, which exhibits proto-oncogenic functions, and several studies have previously validated that the tumorigenesis of bladder cancer has frequently occurred through c-jun relevant signaling pathways [30–34]. Moreover, Chen et al. reported that TMP2 expression was significantly decreased in bladder cancer [35], which was in accordance with our findings that demonstrated the strong positive correlation between TPM2 and CFL2 expressions, where CFL2 was also found to be downregulated in bladder cancer with the lowest FDR. CFL2 has also been reported to act as a tumor suppressor gene in nasopharyngeal carcinoma, pancreas cancer, and gastric cancer [36–38]. Although the functions of CFL2 in bladder cancer has not yet been studied comprehensively, our results indicated that it is a promising novel and potentially meaningful biomarker for exploring new mechanisms in bladder cancer.

As we know, clinicopathological features such as grading and staging are systematic and important prognostic factors in bladder cancer, but their relationship to gene expression profiles remains unclear. In our study, we constructed a bladder cancer specific ceRNA network and analyzed the differentially expressed mRNAs and endogenous RNAs in relation to tumor grades and stages. As a result, we identified that 2 mRNAs and 10 IncRNAs were significantly associated to high-grade tumors and different stages. However, in survival analyses, only HOXB5 and 6 IncRNAs (ADAMTS9-AS1, AC112721.1, LINC00460, AC110491.1, LINC00163, HCG22) were related to overall survival. Although HOXB5 is upregulated in bladder cancer correlating with high-grade and high-stage tumors and has a miRNA-7-binding site of HOXB5 3’-UTR SNP [39], the mechanisms of HOXB5 in bladder cancer remains to be further explored in future studies. Of the survival related IncRNAs in our study, Ye et al. previously demonstrated that LINC00460 could facilitate tumor progression by acting as a sponge to miR-302c-5p and thereby regulating FOXA1 signaling pathway in human lung adenocarcinoma; LINC00460 has also been implicated in promoting malignant biological behaviors in gastric cancer by regulating KDM2A expression through the targeting of miR-342-3p [40,41]. However, none of the 6 survival-related IncRNAs have been reported in bladder cancer. In summary, we identified that HOXB5, ADAMTS9-AS1, AC112721.1, LINC00460, AC110491.1, LINC00163, and HCG22 were related to overall survival in bladder cancer. These genes could be promising future biomarkers for diagnosis, prognostication, and also neotherapeutic targets in bladder cancer.

Conclusions

We have identified a large number of differentially expressed mRNAs, IncRNAs, and miRNAs in bladder cancer which were strongly associated with oncogenesis and prognosis. Many of these RNAs have not been reported in the current literature as related to bladder cancer and represent novel and promising future targets. However, larger cohorts of patients and future mechanistic studies are necessary to validate our results, and investigate their functional roles in bladder cancer.

Conflicts of interest

None.
Supplementary Figure

(A) Three mRNAs expressions were unrelated to tumor stages. (B) Eleven lncRNAs expressions were unrelated to tumor stages. (C) Six mRNAs expressions were unrelated to tumor stages.

References:

1. Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: How far have we come? Cancer J Clin, 2010; 60(4): 244–72
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. Cancer J Clin, 2018; 68(1): 7–30
3. Barton MK: High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer. Cancer J Clin, 2013; 63(6): 371–72
4. Kamat AM, Hahn NM, Efstathiou JA et al: Bladder cancer. Lancet, 2016; 388(10061): 2796–810
5. Cheng L, MacLennan GT, Lopez-Beltran A: Histologic grading of urothelial carcinoma: A reappraisal. Hum Pathol, 2012; 43(12): 2097–108
6. Tuna B, Yorukoglu K, Duzcan E et al: Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility. Virchows Arch, 2011; 458(6): 659–64
7. Chang SS, Boorjian SA, Chou R et al: Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SOU guideline. J Urol, 2016; 196(4): 1021–29
8. Racioppo M, D’Agostino D, Tota A et al: Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int, 2012; 88(3): 249–58
9. Miremami I, Kyprianou N: The promise of novel molecular markers in bladder cancer. Int J Mol Sci, 2014; 15(12): 23897–908
10. Moss TJ, Qi Y, Xi L et al: Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol, 2017; 72(4): 641–49
11. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E et al: Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet, 2013; 45(12): 1464–69
12. Gui Y, Guo G, Huang Y et al: Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet, 2011; 43(9): 875–78
13. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014; 507(7492): 315–22
14. Maeda S, Tomiyasu H, Tsboi M et al: Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC Cancer, 2018; 18(1): 472
15. Chen Y, Peng Y, Xu Z et al: LncROR promotes bladder cancer cell proliferation, migration, and epithelial-mesenchymal transition. Cell Physiol Biochem, 2017; 41(6): 2399–410
16. Liu D, Li Y, Luo G et al: LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett, 2017; 388: 281–91
17. McCarter JP, Mitreva MD, Martin J et al: Analysis and functional classification of transcripts from the nematode Meloidogyne incognita. Genome Biol, 2003; 4(4): R26
18. Salmena L, Poliseno L, Tay Y et al: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell, 2011; 146(3): 353–58
19. Hsu SD, Tseng YT, Shrestha S et al: miRTarBase update 2014: An information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res, 2014; 42(Database issue): D78–85
20. Betel D, Koppal A, Agius P et al: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol, 2010; 11(8): R90
21. Wang Z, Wu Q, Feng S et al: Identification of four prognostic lncRNAs for survival prediction of patients with hepatocellular carcinoma. Peer J, 2017; 5: e3575
22. Baek HB, Lombard AP, Libertini SJ et al: XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget, 2018; 9(77): 34567–81
23. Li Y, Zheng F, Xiao X et al: CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep, 2017; 18(9): 1646–59
24. Cotton S, Azavedo R, Galteiro C et al: Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours. Mol Oncol, 2017; 11(8): 895–912
25. Jiang T, Guo J, Hu Z et al: Identification of potential prostate cancer-related pseudogenes based on competitive endogenous RNA network hypothesis. Med Sci Monit, 2018; 24: 4213–39

26. Yeh CY, Shin SM, Yeh HH et al: Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras-and Src-independent mechanism in human bladder cancer. BMC Cancer, 2011; 11: 139

27. Huang HB, Jiang SC, Han J et al: A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol, 2014; 140(7): 1067–73

28. Fankhauser CD, Mostafid H: Genetic polymorphisms may explain association between alcohol consumption and bladder cancer risk in East Asian men. Transl Androl Urol, 2018; 7(Suppl. 2): S252–54

29. Padmavathi G, Banik K, Monisha J et al: Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression. Cancer Lett, 2018; 432: 260–71

30. Liu J, Zhai R, Zhao J et al: Programmed cell death 4 overexpression enhances sensitivity to cisplatin via the JNK/c-Jun signaling pathway in bladder cancer. Int J Oncol, 2018 [Epub ahead of print]

31. Huang XL, Zhang H, Yang XY et al: Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells. Anticancer Drugs, 2017; 28(6): 596–602

32. Yuan F, Xu Z, Yang M et al: Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer. PLoS One, 2013; 8(7): e69117

33. Li Z, Zhu Y, Yu M et al: c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells. Urol Oncol, 2013; 31(2): 228–33

34. Lee SJ, Kim SK, Choi WS et al: Cordycepin causes P21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells. Arch Biochem Biophys, 2009; 490(2): 103–9

35. Chen R, Feng C, Xu Y: Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res, 2011; 39(2): 533–40

36. Yu BB, Lin GX, Li L et al: Cofilin-2 acts as a marker for predicting radiotherapy response and is a potential therapeutic target in nasopharyngeal carcinoma. Med Sci Monit, 2018; 24: 2317–29

37. Wang Y, Kuramitsu Y, Ueno T et al: Differential expression of up-regulated Cofilin-1 and downregulated Cofilin-2 characteristic of pancreatic cancer tissues. Oncol Rep, 2011; 26(6): 1595–99

38. Bian Y, Guo J, Qiao L, Sun X: miR-3189-3p mimics enhance the effects of S100A4 siRNA on the inhibition of proliferation and migration of gastric cancer cells by targeting CFL2. Int J Mol Sci, 2018; 19(1): pii: E326

39. Luo J, Cai Q, Wang W et al: A microRNA-7 binding site polymorphism in HOXB5 leads to differential gene expression in bladder cancer. PLoS One, 2012; 7(6): e40127

40. Ye JJ, Cheng YL, Deng JJ et al: LncRNA LINCO0460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis. Gene, 2018; 685: 76–84

41. Wang F, Liang S, Liu X et al: LINCO0460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer. Onco Targets Ther, 2018; 11: 6383–94